title: [Antiaggregation agents in the prevention of venous graft occlusion in arterial reconstruction].
abstract: Activated platelets are the most important factor in all 3 occlusive processes which successively take place in venous graft in arterial reconstruction. Therefore antithrombotic therapy, and especially aspirin, receives more and more attention in prolonging the life of the grafts. The first prerequisite for optimal clinical effect of aspirin is the beginning of therapy before or on the day of the operation. The second prerequisite is related to the dose (300 mg), which achieves the fast and complete inhibition of thromboxane production with partial and transient inhibition of prostacyclin production with elimination of undesired effects like the prolongation of bleeding time, greater depression of prostacyclin synthesis and gastric bleeding.
authors: S
authors: S
authors: Anojcić
authors: S
authors: S
authors: Pavlović
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D014680:Veins / Q000637:transplantation*
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin
vernacular_title: Antiagregacijski lekovi u sprecavanju okluzije venskog transplantata kod arterijskih rekonstrukcija.